News | February 27, 2012

First European PAD Patient Enrolled in Forward-Looking OCT Trial

Avinger Inc. announced the enrollment of the first European patient in the CONNECT II global clinical trial. The first patient was enrolled by Dr. Bernhard Reimers at Ospedale di Mirano in Mirano, Italy.

CONNECT II is a multicenter, nonrandomized global clinical study designed to evaluate the safety and efficacy of Ocelot, Avinger’s first therapeutic catheter to incorporate the real-time intravascular imaging technology called optical coherence tomography (OCT). Currently CE-marked, Ocelot is designed for crossing completely blocked arteries, or chronic total occlusions (CTOs), in the legs while simultaneously using OCT to visualize inside the arteries. Ocelot is the first CTO-crossing catheter to incorporate OCT.

“Ocelot and CONNECT II is our first step toward incorporating intravascular imaging into therapeutic catheters. We truly believe this will revolutionize the treatment of vascular disease and amputation prevention,” said Avinger founder and CEO John B. Simpson.

As part of the trial, an independent group of physicians will review the angiography results to determine crossing efficacy and safety. Conditional U.S. Food and Drug Administration (FDA) approval to conduct the study was received Jan. 27, 2012. Co-principal investigators for the trial include Arne Schwindt of St. Franziskus Hospital in Muenster, Germany, and Matthew Selmon, M,D,, Austin Heart Hospital in Austin, Texas.

For more information: avinger.com

Related Content

Pregnancy-Related Heart Failure Strikes Black Women Twice as Often as Other Races
News | Womens Healthcare| October 19, 2017
African American women were found to be twice as likely to be diagnosed with peripartum cardiomyopathy as compared to...
MRI May Predict Neurological Outcomes for Cardiac Arrest Survivors
News | Sudden Cardiac Arrest| October 18, 2017
Magnetic resonance imaging (MRI)-based measurements of the functional connections in the brain can help predict long-...
Xarelto Significantly Reduces Major Cardioavascular Events in Stable CAD and PAD Patients
News | Pharmaceuticals| October 18, 2017
October 18, 2017 — Results from the pivotal Phase 3 COMPASS study found that the...
First Patient Enrolled in U.S. Arm of ALIVE Pivotal Heart Failure Trial
News | Heart Failure| October 17, 2017
October 17, 2017 — BioVentrix Inc. recently announced enrollment of the first patient in the U.S.
Low Mortality and Stroke Risks Displayed for Minimally Invasive Aortic Valve Replacements
News | Heart Valve Technology| October 11, 2017
An analysis of more than 1,000 minimally invasive aortic valve replacements and more than 400 additional associated...
New Evaluation Sends Low-Risk ER Chest Pain Patients Home Sooner
News | Cardiac Diagnostics| October 10, 2017
A new evaluation to determine whether emergency room patients with chest pain can go home and follow up with their...
Videos | Chronic Total Occlusion (CTO)| October 09, 2017
Bill Lombardi, M.D., director of complex coronary artery interventions at the University of Washington, discusses the
News | Pharmaceuticals| October 04, 2017
October 4, 2017 — MyoKardia Inc.
Medtronic Announces Post-Market Study for CoreValve Evolut Pro System
News | Heart Valve Technology| October 02, 2017
Medtronic plc recently announced a new post-market clinical study to evaluate its CoreValve Evolut Pro valve in...
Avinger Receives CE Mark for In-Stent Restenosis Indication With Pantheris Image-Guided Atherectomy
Technology | Atherectomy Devices| September 29, 2017
Avinger Inc. recently announced Conformité Européenne (CE) Marking approval for treating in-stent restenosis with the...
Overlay Init